Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Net Income (2016 - 2025)

Historic Net Income for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to -$30.6 million.

  • Avalo Therapeutics' Net Income fell 23293.83% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 115506.41%. This contributed to the annual value of -$35.1 million for FY2024, which is 1136.51% down from last year.
  • Avalo Therapeutics' Net Income amounted to -$30.6 million in Q3 2025, which was down 23293.83% from -$20.8 million recorded in Q2 2025.
  • Avalo Therapeutics' Net Income's 5-year high stood at $98.5 million during Q2 2024, with a 5-year trough of -$121.3 million in Q1 2024.
  • Its 4-year average for Net Income is -$8.7 million, with a median of -$8.2 million in 2023.
  • The largest annual percentage gain for Avalo Therapeutics' Net Income in the last 5 years was 130179.42% (2024), contrasted with its biggest fall of 111838.27% (2024).
  • Over the past 4 years, Avalo Therapeutics' Net Income (Quarter) stood at -$65000.0 in 2021, then tumbled by 12466.15% to -$8.2 million in 2023, then tumbled by 332.65% to -$35.3 million in 2024, then grew by 13.34% to -$30.6 million in 2025.
  • Its Net Income was -$30.6 million in Q3 2025, compared to -$20.8 million in Q2 2025 and -$13.1 million in Q1 2025.